US medical devices industry sees a drop of 41.4% in deal activity in February 2019

21 March 2019 (Last Updated March 22nd, 2019 04:20)

US medical devices industry sees a drop of 41.4% in deal activity in February 2019

The US medical devices industry saw a drop of 41.4% in overall deal activity during February 2019, when compared with the last 12-month average, according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the code below into your website to display the chart.

A total of 41 deals worth $6.15bn were announced in February 2019, compared to the 12-month average of 70 deals.

Venture financing was the leading category in the month in terms of volume with 31 deals which accounted for 75.6% of all deals.

In second place was M&A with nine deals, followed by private equity with one transactions, respectively accounting for 22% and 2.4% of overall deal activity in the country’s medical devices industry during the month.

In terms of value of deals, M&A was the leading deal category in the US medical devices industry with total deals worth $5.85bn, while venture financing deals totalled $300.21m.

US medical devices industry deals in February 2019: Top deals

The top five medical devices industry deals accounted for 99.1% of the overall value during February 2019.

The combined value of the top five medical devices industry deals stood at $6.1bn, against the overall value of $6.15bn recorded for the month. The top announced US medical devices industry deal tracked by GlobalData in February 2019 was Johnson & Johnson’s $5.75bn acquisition of Auris Health.

In second place was the $102.11m acquisition of CAS Medical Systems by Edwards Lifesciences and in third place was Kaiser Permanente Ventures, Norwest Venture Partners XII, Orbimed Advisors, Sands Capital Ventures, Sequoia Capital Operations and UPMC Enterprises’ $100m venture financing of Health Catalyst.

The $79m venture financing of Nuvaira by Advanced Technology Ventures, Endeavour Vision, LSV Capital Management, Morgenthaler Ventures, Qiming Venture Partners USA, Richard King Mellon Foundation, Split Rock Partners, USVP Management, Versant Venture Management, Vertex Venture Holdings and Windham Venture Partners and Claremont Creek Ventures, Foresite Capital Management, GV Management, Innovatus Capital Partners, WuXi NextCODE Genomics and TPG Biotech’s venture financing of DNAnexus for $68m held fourth and fifth positions, respectively.

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.

Verdict makes every effort to ensure the accuracy of its deals information. If you spot a mistake, or would like to notify us of a deal which should be included in this analysis, please email us at [email protected]

GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.

More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.